ETON

Eton Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

17.050

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

17.050

Open

17.050

VWAP

17.05

Vol

1.38K

Mkt Cap

457.24M

Low

17.050

Amount

23.49K

EV/EBITDA(TTM)

Total Shares

25.69M

462.04M

EV/OCF(TTM)

37.76

P/S(TTM)

7.80

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

20.47M

+98.31%

21.82M

+87.35%

24.14M

+39.68%

Estimates Revision

The market is revising Upward the revenue expectations for Eton Pharmaceuticals, Inc. (ETON) for FY2025, with the revenue forecasts being adjusted by 7.91% over the past three months. During the same period, the stock price has changed by -1.73%.

Revenue Estimates for FY2025

Revise Upward

+7.91%

In Past 3 Month

Stock Price

Go Down

-1.73%

In Past 3 Month

4 Analyst Rating

48.56% Upside

Wall Street analysts forecast ETON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETON is 25.33 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

48.56% Upside

Current: 17.050

Low

15.00

Averages

25.33

High

35.00

48.56% Upside

Current: 17.050

Low

15.00

Averages

25.33

High

35.00

H.C. Wainwright

Buy

maintain

$33 -> $35

2025-05-29

Reason

H.C. Wainwright

Price Target

$33 -> $35

2025-05-29

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Eton Pharmaceuticals to $35 from $33 and keeps a Buy rating on the shares after the company announced that Khindivi received FDA approval as replacement therapy in pediatric patients five years of age and older with adrenal insufficiency. The firm believes 2025 could be a year of revenue inflection for Eton.

B. Riley

Buy

maintain

$24 -> $26

2025-05-16

Reason

B. Riley

Price Target

$24 -> $26

2025-05-16

maintain

Buy

Reason

B. Riley raised the firm's price target on Eton Pharmaceuticals to $26 from $24 and keeps a Buy rating on the shares. The company reported strong Q1 results across its portfolio, the analyst tells investors in a research note. The firm continues to view the reaffirmed $80M year-end run-rate guidance as conservative, and sees "two high-conviction opportunities to drive upward revisions" closer to $100M.

Craig-Hallum

Buy

maintain

$26 -> $28

2025-05-14

Reason

Craig-Hallum

Price Target

$26 -> $28

2025-05-14

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Eton Pharmaceuticals to $28 from $26 and keeps a Buy rating on the shares following Q1 earnings, which was another strong performance. The company reiterated an $80M run-rate goal by year-end, though the firm sees this as conservative based on current trends and has modeled slightly above this level.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$33

2025-03-19

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$33

2025-03-19

Reiterates

Strong Buy

Reason

B. Riley Securities

Madison El-Saadi

Strong Buy

Reiterates

$21 → $24

2025-03-19

Reason

B. Riley Securities

Madison El-Saadi

Price Target

$21 → $24

2025-03-19

Reiterates

Strong Buy

Reason

B. Riley raised the firm's price target on Eton Pharmaceuticals to $24 from $21 and keeps a Buy rating on the shares. The pullback following Eton's quarterly earnings report is likely due to $80M run-rate guidance vs. the $100M buy-side number, though this overlooks the conservative nature of the guidance that excludes the ET-400 contribution in FY25, providing a nice entry opportunity, the analyst tells investors in a research note. The firm sees a three-step path to $100M/$300M in annual revenue run-rate by 1Q26/1Q28.

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$23 → $26

2025-03-19

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$23 → $26

2025-03-19

Maintains

Strong Buy

Reason

Craig-Hallum raised the firm's price target on Eton Pharmaceuticals to $26 from $23 and keeps a Buy rating on the shares following the company's Investor Day and Q4 earnings results. Revenue for Q4 was $11.6M, beating Street expectations of $10.5M, with GAAP EPS at ($0.02) vs. ($0.00). Management provided 2025 guidance, targeting an $80M annual revenue run rate by year-end and a path to exceeding $100M in the near term, driven by acquisitions, Alkindi growth, and ET-400 launch, the firm notes. Investor Day showcased significant revenue potential, with management highlighting nearly $500M in peak sales from the portfolio and pipeline, adds Craig-Hallum.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Eton Pharmaceuticals Inc (ETON.O) is 23.24, compared to its 5-year average forward P/E of 21.90. For a more detailed relative valuation and DCF analysis to assess Eton Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

21.90

Current PE

23.24

Overvalued PE

114.57

Undervalued PE

-70.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-91.64

Current EV/EBITDA

15.10

Overvalued EV/EBITDA

385.08

Undervalued EV/EBITDA

-568.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.18

Current PS

4.91

Overvalued PS

6.77

Undervalued PS

1.59

Financials

Annual

Quarterly

FY2025Q2

YoY :

+108.60%

18.93M

Total Revenue

FY2025Q2

YoY :

-288.38%

5.53M

Operating Profit

FY2025Q2

YoY :

-15.00%

-2.59M

Net Income after Tax

FY2025Q2

YoY :

-16.67%

-0.10

EPS - Diluted

FY2025Q2

YoY :

+534.18%

7.96M

Free Cash Flow

FY2025Q2

YoY :

+61.29%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

-184.53%

7.05

FCF Margin - %

FY2025Q2

YoY :

-59.24%

-13.66

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.1M

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

125.5K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

1.0M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

109.7K

Volume

Months

6-9

1.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.1M

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

125.5K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

1.0M

USD

Months

ETON News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

16:36:28

Eton Pharmaceuticals reports Q2 non-GAAP EPS 3c, consensus 2c

2025-07-08 (ET)

2025-07-08

06:53:07

Eton Pharmaceuticals' NDA for ET-600 solution accepted by FDA

2025-06-27 (ET)

2025-06-27

06:51:34

Eton Pharmaceuticals to be added to Russell 2000, Russell 3000 Indexes

News

9.0

07-08NASDAQ.COM

FDA Accepts Eton Pharma's NDA For ET-600 Desmopressin Oral Solution

9.0

07-08SeekingAlpha

Eton gains as hormonal disorder therapy undergoes FDA review

2.0

06-27NASDAQ.COM

Eton Pharmaceuticals Added to Russell 3000® and Russell 2000® Indexes as Part of 2025 Reconstitution

People Also Watch

APEI

American Public Education Inc

Gilat Satellite Networks Ltd

POET Technologies Inc

Allogene Therapeutics Inc

America's CAR-MART Inc

First Business Financial Services Inc

47.290

USD

0.00%

FAQ

What is Eton Pharmaceuticals Inc (ETON) stock price today?

The current price of ETON is 17.05 USD — it has increased 0 % in the last trading day.

ETON

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ETON News & Events

Events Timeline

News

People Also Watch

FAQ

What is Eton Pharmaceuticals Inc (ETON) stock price today?

What is Eton Pharmaceuticals Inc (ETON)'s business?

What is the price predicton of ETON Stock?

What is Eton Pharmaceuticals Inc (ETON)'s revenue for the last quarter?

What is Eton Pharmaceuticals Inc (ETON)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Eton Pharmaceuticals Inc (ETON)'s fundamentals?

How many employees does Eton Pharmaceuticals Inc (ETON). have?

What is Eton Pharmaceuticals Inc (ETON) market cap?